Indication

Target/marker/pathway

Summary

Licensing status

Publication and
contact information

Cancer

Cancer

Phosphoglycerate mutase 1 (PGAM1)

Mouse and cell culture studies suggest inhibiting PGAM1 could help treat cancer. In a panel of six human cancer cell lines, small hairpin RNA knockdown of PGAM1 decreased proliferation compared with no knockdown. In a mouse xenograft model of human non-small cell lung cancer (NSCLC), pharmacological inhibition of PGAM1 lowered tumor volume compared with no inhibition. In patient samples, the PGAM1 inhibitor decreased viability of primary acute and chronic myelogenous leukemia cells compared with vehicle. Next steps include additional SAR studies to improve the pharmacokinetics and bioavailability of the PGAM1 inhibitors.

SciBX 5(46); doi:10.1038/scibx.2012.1204
Published online Nov. 29, 2012

Patent pending; available for licensing from the Emory University
Office of Technology Transfer

Hitosugi, T. et al. Cancer Cell; published online Nov. 13, 2012;
doi:10.1016/j.ccr.2012.09.020
Contact: Jing Chen, Emory University School of Medicine, Atlanta, Ga.
e-mail:
jchen@emory.edu
Contact: Chuan He, The University of Chicago, Chicago, Ill.
e-mail:
chuanhe@uchicago.edu